📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved substantial reductions in MRI inflammation at Wk 16 main
Tweet Content
📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved
substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52.
-PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52.
Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off